Insights into relationships between serum ferritin and liver iron concentration trends during 12 months of iron chelation therapy with deferasirox - a post-hoc analysis from the epic study
Saved in:
Main Authors: | Porter, J.B., Elalfy, M., Taher, A.T., Chan, L.L., Lee, S.H., Sutcharitchan, P., Aydinok, Y., Chakravarty, S., El-Ali, A., El-Beshlawy, A. |
---|---|
Format: | Article |
Published: |
The American Society of Hematology
2014
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/15411/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
by: Cappellini, M.D., et al.
Published: (2010) -
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
by: Pennell, D.J., et al.
Published: (2010) -
Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
by: Pennell, D., et al.
Published: (2010) -
Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis
by: Pennell, D., et al.
Published: (2010) -
Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B OR C
by: Cappellini, M.D., et al.
Published: (2010)